1. Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY;
2. Dana-Farber Cancer Institute, Boston, MA;
3. Department of Data Science, Harvard T. H. Chan School of Public Health, Boston, MA;
4. Instituto de Investigación, Hospital Universitario 12 de Octubre (i+12), Madrid, Spain;
5. Centro Nacional de Investigaciones Oncológicas (CNIO), Complutense University, Madrid, Spain;
6. Leeds Institute of Clinical Trial Research and
7. Leeds Cancer Centre, University of Leeds, Leeds, United Kingdom;
8. John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ;
9. Department of Haematology, University College London Hospitals National Health Service (NHS) Foundation Trust, London, United Kingdom;
10. Clínica São Germano, São Paulo, Brazil;
11. Medical Department,
12. Hematology, Oncology and Stem Cell Transplantation, and
13. Clinical Cancer Research Group, Faculty of Medicine, University of Freiburg, Freiburg, Germany;
14. Myeloma Unit, Division of Hematology, University of Turin/Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Turin, Italy;
15. Department of Hematology, Hospital de Manises, Valencia, Spain;
16. Hematology Laboratory, University of Turin, Turin, Italy;
17. Department of Haematology, University Medical Centre, Utrecht, The Netherlands;
18. Department of Hematology, University of Siena, Siena, Italy;
19. Center for Myeloma, New York Presbyterian Hospital-Weill Cornell Medical Center, New York, NY;
20. Division of Hematology, Mayo Clinic, Rochester, MN;
21. Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA;
22. Department of Internal Medicine II, University Hospital of Würzburg, Würzburg, Germany;
23. Department of Hematology, Ankara University, Ankara, Turkey;
24. II Medizinische Klinik, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany;
25. Department of Medical Oncology, Harvard Medical School, Boston, MA;
26. Instituto de Investigación Biomédica de Salamanca (IBSAL), University Hospital of Salamanca, Salamanca, Spain;
27. Department of Hematology, University Hospital Hôtel-Dieu, Nantes, France;
28. Intergroupe Francophone du Myélome (IFM), Paris, France;
29. Clínica Universidad de Navarra and
30. Centro de Investigacion Medica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain;
31. Instituto de Investigacion Sanitaria de Navarra (IDISNA), Pamplona, Spain;
32. Centro de Investigación Biomédica en Red de Cáncer (CIBER-ONC), Pamplona, Spain;
33. US Department of Veterans Affairs (VA) Boston Healthcare System, Boston, MA; and
34. Centre de Recherche en Cancérologie de Toulouse, Unité 1037, INSERM, Toulouse, France